The company said total revenues for Q4 2024 rose 10% to $3,789 million, and full-year total revenues rose 8% to $14,202 million. GAAP net income for Q4 was $918 million, down 21%, and full-year GAAP net income was $4,413 million, up 12%.

1. 01

   The company said total revenues for Q4 2024 rose 10% to $3,789 million, and full-year total revenues rose 8% to $14,202 million. GAAP net income for Q4 was $918 million, down 21%, and full-year GAAP net income was $4,413 million, up 12%.

2. 02

   Regeneron said combined U.S. net sales of EYLEA HD and EYLEA rose 2% to $1,495 million in Q4 2024, and EYLEA HD accounted for $305 million of that total. The company cited a lower net selling price as having had an adverse effect on net sales in Q4 and on full-year net sales.

3. 03

   The company said Sanofi collaboration revenue rose 22% to $1,213 million in Q4 2024, and rose 19% to $4,531 million for the full year. It cited higher profit sharing from antibody commercialization, driven by increased Dupixent sales, as the reason for the increase.

4. 04

   Regeneron said its board initiated a quarterly cash dividend program and declared a dividend of $0.88 per share, payable on March 20, 2025. It also said it approved an additional share repurchase program of $3.0 billion, which brings current repurchase capacity to approximately $4.5 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.